Investor Presentaiton

Investor presentation First three months of 2017 Slide 58 The combined GLP-1 segment accounts for more than 2% of the total diabetes care market in AAMEO AAMEO GLP-1 market VictozaⓇ value market share in AAMEO GLP-1 value in bDKK VictozaⓇ dulaglutide lixisenatide Share of total exenatide diabetes care market GLP-1 value market share VictozaⓇ dulaglutide lixisenatide exenatide 0.5 3% 100% CAGR value¹: 38.0% 0.4 80% - 2% 0.3 60% 55% 0.2 40% 1% 0.1 20% 0.0 0% 0% Feb 2012 Feb 2017 1 CAGR for 5-year period AAMEO: Africa, Asia, the Middle East and Oceania Source: IMS Monthly MAT February, 2017 value figures (DKK) Feb 2012 Source: IMS Monthly MAT February, 2017 value figures (DKK) 28% .16% 0% Feb 2017 changing diabetes® novo nordisk

View entire presentation